{"title":"Steroid-related emphysematous cystitis in an EGFR-mutant patient with lung adenocarcinoma while on gefitinib treatment","authors":"Diego Marquez-Medina , Sanjay Popat","doi":"10.1016/j.ctrc.2015.06.003","DOIUrl":null,"url":null,"abstract":"<div><p>Advanced non-small cell lung cancer (NSCLC), the most lethal malignancy worldwide, obtains a small long-term benefit from chemotherapy. However, 16% of Caucasian patients presenting sensitizing mutations in the epidermal growth factor receptor have a high sensitivity to the tyrosine kinase inhibitor gefitinib. Gefitinib is a safe drug, with mild diarrhea, emesis, or skin rash the most common toxicities. However, rare adverse events such as <em>pneumatosis intestinalis</em> have been communicated. We first report a very rare case of emphysematous cystitis in a female patient with <em>EGFR</em>-mutant lung adenocarcinoma while on gefitinib treatment, taken advance to review risk factors for this infectious complication.</p></div>","PeriodicalId":90461,"journal":{"name":"Cancer treatment communications","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ctrc.2015.06.003","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213089615300037","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Advanced non-small cell lung cancer (NSCLC), the most lethal malignancy worldwide, obtains a small long-term benefit from chemotherapy. However, 16% of Caucasian patients presenting sensitizing mutations in the epidermal growth factor receptor have a high sensitivity to the tyrosine kinase inhibitor gefitinib. Gefitinib is a safe drug, with mild diarrhea, emesis, or skin rash the most common toxicities. However, rare adverse events such as pneumatosis intestinalis have been communicated. We first report a very rare case of emphysematous cystitis in a female patient with EGFR-mutant lung adenocarcinoma while on gefitinib treatment, taken advance to review risk factors for this infectious complication.